FDA Panel Endorses Arena's New Obesity Drug

Law360, New York (May 10, 2012, 7:06 PM EDT) -- A panel of U.S. Food and Drug Administration scientists gave its endorsement to Arena Pharmaceuticals Inc.'s obesity drug lorcaserin on Thursday, finding that the potential benefits of the medication outweigh the risks.

In an 18-4 vote with one abstention, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee said the available data supported approval of the drug. If the agency takes up the committee’s recommendation, lorcaserin could become the first obesity drug approved by the FDA since Roche Holding AG's Xenical in 1999.

"The advisory committee's positive...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.